GENE ONLINE|News &
Opinion
Blog

Targeted Radioligand Therapy
Partnerships OncologyRadiopharmaceutical
Eli Lilly and Aktis Oncology Partner to Advance Novel Radiopharmaceuticals
2024-05-22
M&A Eli LillyRadiopharmaceutical
Eli Lilly Expands Oncology Portfolio with $1.4 Billion Acquisition of POINT Biopharma
2023-10-04
Interviews Rakuten Medical
Defeating Head and Neck Cancer, From Combination Therapy to Photoimmunotherapy
2022-09-15
Day 3 ASCO 2021 Roundup: Lynparza, Keytruda and Novartis’ Radioligand Therapy Take Honors in Plenary Session
2021-06-09
Trials & Approvals Targeted Radioligand Therapy
Novartis’ Acquired Asset from Endocyte Shines in Phase 3 Prostate Cancer Trial
2021-03-24
LATEST
Eli Lilly’s Orforglipron Shows Phase 3 Success: First Oral GLP-1 Drug for Type 2 Diabetes and Weight Loss
2025-04-21
Dupixent Makes History with FDA Approval as First New CSU Treatment in Over a Decade
2025-04-20
Multiple PCV Doses May Be Needed for Immunocompromised Type 2 Diabetics to Maintain Protection, Study Finds
2025-04-19
Multiple PCV Doses May Be Needed for Immunocompromised Individuals with Type 2 Diabetes
2025-04-19
Dr. Lauren Krupp, FAAN, Advocates Early Intervention and Family Support in Pediatric MS Treatment.
2025-04-19
Dr. Lauren B. Krupp Recommends Early, Aggressive Treatment with High-Efficacy Therapies for Pediatric Multiple Sclerosis
2025-04-19
GSK’s Blenrep Scores World-First Approval in UK for Multiple Myeloma
2025-04-17
READ MORE
EVENT
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
2025-04-26
SABPA OC/LA 17th Annual Biomedical Forum
Irvine, California, United States
2025-05-03
29th Taiwan Joint Cancer Conference 2025
Taipei, Taiwan
2025-05-05
Swiss Biotech Day 2025
Basel, Switzerland
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2025 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top